A Study between 0.5 percent Ropivacaine and 0.5 percent Ropivacaine with Verapamil as an adjuvant in USG guided supraclavicular brachial plexus block in upper limb surgeries.

A Randomised Comparative Study between 0.5 percent Ropivacaine and 0.5 percent Ropivacaine with Verapamil as an adjuvant in Ultrasound guided supraclavicular brachial plexus block in upper limb surgeries. - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/10/075672

Enrollment

Registered

2024-10-23

Start date

Unknown

Completion date

Unknown

Last updated

2024-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: S500- Contusion of elbow Health Condition 2: S602- Contusion of wrist and hand Health Condition 3: S614- Open wound of hand Health Condition 4: S503- Other superficial injuries of elbow Health Condition 5: S629- Unspecified fracture of wrist andhand

Interventions

Intervention1: 0.5 Percent Ropivacaine: Inj Ropivacaine 0.5 percent (30ml) with normal saline (1ml) in USG guided supraclavicular brachial plexus block in upper limb surgeries from the injection of d

Eligibility

Inclusion criteria

Inclusion criteria: 1. Adult patients aged between 18-60 years. 2. American society of Anesthesiologists (ASA) Physical Status I and II. 3. Patient weighing between 50kgs-80kg 4. Patients scheduled for elective upper limb surgeries under Supraclavicular block.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
1. To study the onset and duration of sensory blockade 2. To study the onset and duration of motor blockade Timepoint: 1.From the time of injecting the drug till 24 hours.	—

Secondary

Measure	Time frame
1.Time taken for rescue analgesic and dose 2.Haemodynamic parameters 3.Complications if any Timepoint: 6 MONTHS	—

Countries

India

Contacts

Public ContactS Angu Mukunthan

Pacific Medical College and Hospital

angumukunthan1998@gmail.com08015805823

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026